5 Sales Growth Picks Positioned to Generate Steady Returns

With the Fed cutting rates for a third time this year amid sticky inflation, slowing job growth and headwinds from tariffs and supply-chain strains, Zacks argues that retail investors should emphasize sales growth over earnings to identify durable business momentum; revenues are presented as a cleaner early signal of future earnings, cash-flow stability and reinvestment capacity. Zacks outlines screening criteria (5‑year sales growth > industry, cash flow > $500m, P/S < industry, positive four‑week sales estimate revisions vs. industry, operating margin avg >5%, ROE >5%, Zacks Rank ≤2) and highlights five names that meet the approach—Vertiv (VRT, 2025 sales growth est. 27.5%, Zacks #1), RenaissanceRe (RNR, 3.4%, #1), Ameren (AEE, 17.7%, #2), Canadian Natural Resources (CNQ, 5.9%, #2) and FedEx (FDX, 4.6% fiscal 2026, #2)—as candidates for investors seeking companies with sales-driven momentum and cash strength.

Analysis

The article situates Zacks’ recommendation within a macro backdrop of a third Fed rate cut this year amid sticky inflation, slowing job growth, tariffs, supply-chain pressures and uneven business investment, arguing these conditions make earnings-based signals less reliable. It asserts revenue is a cleaner, earlier indicator of demand and future earnings, because sales are less subject to accounting adjustments and better reflect customer traction and reinvestment capacity.

Zacks’ screening framework prioritizes firms with 5‑year sales growth above their industry and cash flow exceeding $500 million, supplemented by P/S below industry, four‑week sales‑estimate revisions outpacing peers, five‑year operating margin average >5%, ROE >5% and Zacks Rank ≤2. These filters are intended to isolate cash-rich, revenue‑driven businesses that can sustain investments and operational leverage despite macro headwinds.

Five names meet the screen: Vertiv (VRT) — expected 2025 sales growth 27.5%, Zacks #1; Ameren (AEE) — 17.7% 2025, #2; RenaissanceRe (RNR) — 3.4% 2025, #1; Canadian Natural (CNQ) — 5.9% 2025, #2; FedEx (FDX) — 4.6% fiscal 2026, #2. The implication for investors is to favor revenue momentum combined with balance‑sheet strength while monitoring sector cyclicality (reinsurance, energy, logistics) and macro revisions that could reverse sales momentum.

Key Decisions for Investors

• Conduct focused due diligence on the five highlighted names (VRT, AEE, RNR, CNQ, FDX) prioritizing verification of the cited sales‑growth trajectories and cash‑flow cushions before adding exposure
• Tilt toward companies that meet the explicit screen (5‑year sales growth > industry, cash flow > $500m, P/S < industry, positive recent sales‑estimate revisions, operating margin avg >5%, ROE >5%, Zacks Rank ≤2) and consider overweighting those with both top‑line momentum and strong cash positions
• Actively monitor four‑week sales‑estimate revisions, operating‑margin trends and macro indicators (inflation, job growth, tariffs, supply‑chain signals) and tighten risk controls or hedge if sales momentum or estimate revisions turn negative
• Limit position sizes or use hedges for cyclical exposures (reinsurance RNR, energy CNQ, logistics FDX) despite revenue strength, given the article’s emphasis on prevailing macro and trade headwinds